359 related articles for article (PubMed ID: 33564942)
1. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
Fralick M; Redelmeier DA; Patorno E; Franklin JM; Razak F; Gomes T; Schneeweiss S
J Gen Intern Med; 2021 Sep; 36(9):2601-2607. PubMed ID: 33564942
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
4. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
8. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
10. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB; Røikjer JB; Dal J; Jensen MH
Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic Diabetic Ketoacidosis: Experience with 44 Patients and Comparison to Hyperglycemic Diabetic Ketoacidosis.
Sell J; Haas NL; Korley FK; Cranford JA; Bassin BS
West J Emerg Med; 2023 Nov; 24(6):1049-1055. PubMed ID: 38165186
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
16. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
[TBL] [Abstract][Full Text] [Related]
18. The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study.
Zhao Q; Tan Y; Wu Q; Xiao X; Wei X; Nian M; Yao J; Fan N; Wang R; Fan G
Expert Opin Drug Saf; 2024 Jan; 23(1):57-65. PubMed ID: 37947121
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.
Clark A; Mohammed AS; Raut A; Moore S; Houlden R; Awad S
Can J Diabetes; 2021 Apr; 45(3):214-219. PubMed ID: 33046401
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]